CO2020005944A2 - Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos - Google Patents

Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos

Info

Publication number
CO2020005944A2
CO2020005944A2 CONC2020/0005944A CO2020005944A CO2020005944A2 CO 2020005944 A2 CO2020005944 A2 CO 2020005944A2 CO 2020005944 A CO2020005944 A CO 2020005944A CO 2020005944 A2 CO2020005944 A2 CO 2020005944A2
Authority
CO
Colombia
Prior art keywords
substituted heterocyclic
methods
amine
synthesis
salts
Prior art date
Application number
CONC2020/0005944A
Other languages
English (en)
Inventor
Kenneth W Duncan
John Emmerson Campbell
James Edward John Mills
Michael John Munchhof
Original Assignee
Epizyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epizyme Inc filed Critical Epizyme Inc
Publication of CO2020005944A2 publication Critical patent/CO2020005944A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente divulgación se refiere a compuestos heterocíclicos sustituidos con amina. La presente divulgación también se refiere a composiciones farmacéuticas que contienen estos compuestos y a métodos para tratar un trastorno (por ejemplo, cáncer) mediante la administración de un compuesto heterocíclico sustituido con amina desvelado en este documento o una composición farmacéutica del mismo en sujetos con necesidad del mismo. La presente divulgación también se refiere al uso de tales compuestos en investigación u otros fines no terapéuticos.
CONC2020/0005944A 2017-10-18 2020-05-15 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos CO2020005944A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573917P 2017-10-18 2017-10-18
PCT/US2018/056428 WO2019079540A1 (en) 2017-10-18 2018-10-18 AMINO-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF EHMT2, SALTS THEREOF, AND METHODS OF SYNTHESIS THEREOF

Publications (1)

Publication Number Publication Date
CO2020005944A2 true CO2020005944A2 (es) 2020-07-31

Family

ID=66173899

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2020/0005944A CO2020005944A2 (es) 2017-10-18 2020-05-15 Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos

Country Status (16)

Country Link
US (2) US20200247790A1 (es)
EP (1) EP3697762A4 (es)
JP (2) JP2021500334A (es)
KR (1) KR20200101330A (es)
CN (1) CN111417628A (es)
AU (2) AU2018353122B2 (es)
BR (1) BR112020007632A2 (es)
CA (1) CA3079273A1 (es)
CL (1) CL2020001009A1 (es)
CO (1) CO2020005944A2 (es)
EA (1) EA202090959A1 (es)
IL (2) IL301746B2 (es)
MA (1) MA50418A (es)
MX (2) MX2020007152A (es)
SG (1) SG11202003225YA (es)
WO (1) WO2019079540A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018221705B2 (en) 2017-02-17 2022-10-27 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
CN118021814A (zh) 2017-04-21 2024-05-14 Epizyme股份有限公司 用ehmt2抑制剂进行的组合疗法
LT3697789T (lt) 2017-10-18 2021-12-10 Incyte Corporation Kondensuoti imidazolo dariniai, pakeisti tretinėmis hidroksigrupėmis, kaip pi3k-gama inhibitoriai
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
CN114249785B (zh) * 2020-09-23 2024-04-05 常州方圆制药有限公司 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法
CN116406268A (zh) * 2020-10-27 2023-07-07 特维娜有限公司 δ-阿片样物质调节剂的结晶和无定形形式

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0414544A (pt) * 2003-09-18 2006-11-07 Novartis Ag 2,4-di-(fenilamino) pirimidinas úteis no tratamento de transtornos proliferativos
BR122021011788B1 (pt) * 2005-11-01 2022-01-25 Impact Biomedicines, Inc Inibidores de biaril meta pirimidina de cinases, composição farmacêutica e processo para preparar uma composição farmacêutica
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US9284272B2 (en) * 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
CN106536509B (zh) * 2014-06-16 2020-06-09 基础应用医学研究基金会 作为组蛋白甲基转移酶和dna甲基转移酶的双重抑制剂的新型化合物
JP2017519017A (ja) * 2014-06-23 2017-07-13 ジェネンテック， インコーポレイテッド 癌の治療及び癌薬剤耐性の防止方法
TWI751155B (zh) * 2016-04-15 2022-01-01 美商雅酶股份有限公司 經胺取代之芳基或雜芳基化合物
PL3555070T3 (pl) * 2016-12-19 2023-11-06 Epizyme, Inc. Związki heteroarylowe podstawione aminą jako inhibitory ehmt2 i sposoby ich zastosowania
AU2018243749A1 (en) * 2017-03-31 2019-11-21 Epizyme, Inc. Methods of using EHMT2 inhibitors
JP2021500327A (ja) * 2017-10-18 2021-01-07 エピザイム，インコーポレイティド 免疫療法にｅｈｍｔ２阻害剤を使用する方法

Also Published As

Publication number Publication date
AU2024201165A1 (en) 2024-03-14
MX2020007152A (es) 2020-12-10
EP3697762A1 (en) 2020-08-26
KR20200101330A (ko) 2020-08-27
EP3697762A4 (en) 2021-04-07
IL301746B1 (en) 2024-09-01
CN111417628A (zh) 2020-07-14
CA3079273A1 (en) 2019-04-25
AU2018353122A1 (en) 2020-06-04
IL273974A (en) 2020-05-31
IL301746B2 (en) 2025-01-01
IL273974B2 (en) 2023-08-01
WO2019079540A1 (en) 2019-04-25
IL273974B1 (en) 2023-04-01
EA202090959A1 (ru) 2020-07-13
CL2020001009A1 (es) 2020-12-18
JP2021500334A (ja) 2021-01-07
BR112020007632A2 (pt) 2020-09-29
US20200247790A1 (en) 2020-08-06
JP2023036991A (ja) 2023-03-14
AU2018353122B2 (en) 2023-11-23
IL301746A (en) 2023-05-01
MA50418A (fr) 2021-04-07
US20220324851A1 (en) 2022-10-13
MX2024012124A (es) 2025-02-10
SG11202003225YA (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CO2019006787A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2 y métodos de uso de los mismos
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
CO2018012181A2 (es) Compuestos arilo o heteroarilo sustituidos con amino como inhibidores de ehmt1 y ehmt2
CL2023002682A1 (es) Uso de inhibidores de ehmt2 para tratar trastornos sanguíneos
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
BR112015021983A2 (pt) compostos heterocíclicos e usos dos mesmos
BR112019006712A2 (pt) composto, composição farmacêutica, composição para uso no tratamento de uma doença, elemento implantável, e, dispositivo.
BR112018005497A2 (pt) compostos heterocíclicos e usos dos mesmos
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
MX2020012695A (es) Compuestos de benceno substituidos con arilo o heteroarilo.
MX2018000179A (es) Formas solidas y formulaciones de (s)-4-(8-amino-3-(1-(but-2-inoil )pirrolidin-2-il)imidazo[1,5-a]pirazin-1-il)-n-(piridin-2-il)benz amida.
DOP2018000062A (es) Piridinona dicaboxamidas para uso como inhibidores de bromodominio
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
EA201592068A1 (ru) Ингибиторы энхансера zeste гомолога 2
BR112015030515A2 (pt) intensificadores de inibidores de homólogo 2 de zeste
AR100431A1 (es) Compuestos de pladienolida piridina y métodos de uso
TR201908265T4 (tr) Isı şok transkripsiyon faktörü 1 in inhibitörleri olarak kaynaşık 1,4-dihidrodioksin türevleri.
AU2017269673A1 (en) Pyridine dicarboxamide derivatives as bromodomain inhibitors
BR112017028616A2 (pt) acentuador de inibidores de homólogo de zeste 2
BR112017005242A2 (pt) composto, composição farmacêutica, e, composto para uso.
UY37837A (es) Nuevos compuestos heterocíclicos como inhibidores de cdk8/19
MX2018002898A (es) Compuestos utiles para inhibir ror-gamma-t.
UY37191A (es) Derivados de dibenzofurano para uso como inhibidores de bromodominio
EA201600394A1 (ru) Трициклические соединения пиперидина